7G BioVentures — Full Portfolio

Aqualung Therapeutics is an early-stage therapeutics company developing a drug discovery platform and pipeline focused on advancing human health.

BiotechHealthtechMedical DevicesTucson, US

Joe G.N. Garcia(Executive Officer, Director)Stan Miele(President)Joe G.N. "Skip" Garcia(Founder & Chief Executive Officer)Shawntela Martinez(Chief Financial Officer (Fractional))Augustine Choi(Chief Medical Officer (Fractional))

Clinical-stage biopharmaceutical company developing best-in-class aryl hydrocarbon receptor agonists.

Improving how hospitals manage, store, and deliver breast milk to infants most in need.

BBy develops a method to shelf-stabilize and condense human breast milk without losing its nutritional or immunological properties, removing the need for freezer storage in hospital NICUs.

BiotechHealthtechMedical Devices

Co-investorsBeresford Ventures

Software helping clinicians consistently deliver best-practice clinical care.

Developing a best-in-class minimally-invasive treatment for ectatic corneal disease to enable early intervention for patients globally.

Epion Therapeutics is developing EpiSmart, a minimally-invasive corneal cross-linking system to treat keratoconus and corneal ectasia without disrupting the epithelium.

BiotechHealthtechMedical Devices

Co-investorsNew World Angels

A biopharmaceutical company developing a pipeline of long-acting therapeutic candidates, including GLP-1 receptor agonists, amylin DACRAs, a PYY receptor agonist, and a glucagon receptor agonist.

Biotech

Co-investorsCerity Partners VenturesHikma VenturesSanofi Ventures

Developed ionic liquid technology to enable oral delivery of biologics.

Clinical-stage biotechnology company advancing allogeneic CAR-T cell therapies for autoimmune disorders and cancers.

Imviva Bio develops allogeneic CAR-T cell therapies for cancer and autoimmune diseases, using its Imviva platform and ANSWER technology with immune-evasion science aimed at improving cell therapy performance and persistence.

BiotechHealthtech

Kayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology.

BiotechHealthtechSeattle, US

Mark Esposito(CSO, Co-Founder and Board Member)Yibin Kang(Chair, Scientific Advisory Board and Co-Founder)Thong Le(Executive Officer, Director)Kendall Mohler(Executive Officer, Director)Thong Q. Le(President and CEO, Board Member)Ian Howes(Chief Financial Officer)

Co-investorsFoundation Venture Capital Group, LLC

Mesentech develops prostaglandin prodrugs aimed at musculoskeletal regeneration.

BiotechHealthtechVancouver

David Hyman(Executive Officer)Robert Norman Young(Executive Officer, Director)Jay Mohr(Director)David Dvorak(Director)Jonathan Polak(Executive Officer, Director, Promoter)

BoardSamuel Wu(Director)

Co-investorsBeresford VenturesWUTIF Capital

Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity.

BiotechDeep TechHealthtech

Bob Prud'homme(Leadership (PhD))Rob Pagels(Leadership (PhD))Chet Markwalter(Leadership (PhD))Shahram Hejazi(Leadership (PhD))Gregory Harriman(Leadership (MD))Mark Esposito(Leadership (PhD))

Co-investorsAnzu Partners

Innovating enzyme therapeutics for the treatment of digestive and orphan diseases.

Perseo pharma is a preclinical-stage biopharmaceutical company developing oral enzyme therapies for patients with digestive diseases such as exocrine pancreatic insufficiency.

BiotechDeep TechDigital Health

Improving diabetes management by enhancing patient adherence to glucose monitoring.

Persperion Diagnostics develops touch-based sweat sensing technology for diagnostic measurement.

Deep TechDigital HealthMedical Devices

Co-investorsCornucopian Capital ManagementFoothill VenturesSamsung Next